Navigation Links
Innophos Holdings, Inc. Reports First Quarter 2012 Results

CRANBURY, N.J., May 1, 2012 /PRNewswire/ -- Innophos Holdings, Inc. (NASDAQ:   "IPHS"), a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, pharmaceutical, oral care and industrial end markets, today announced its financial results for the first quarter 2012.

First Quarter Results

  • Net sales for the first quarter 2012 were $228 million, a 16% increase over first quarter 2011. 
  • Specialty Phosphates first quarter 2012 sales of $192 million increased 10% compared to first quarter 2011 on higher prices. Specialty Phosphates operating income increased significantly on a sequential basis on improved volumes and margins in the US/Canada business.
  • GTSP & Other sales at $36 million for the 2012 first quarter were $14 million above the year ago level on higher volumes. Lower pricing caused by declining fertilizer market price trends resulted in an operating loss for this segment of $2.5 million; down $6 million versus the prior period.  Early indications for the second quarter are for improving selling prices.
  • As previously reported, during the quarter the company reached a settlement with former parent, Rhodia, on various claims, including a claim for liability for excess water duty charges in Mexico and reduced its estimate on probable amounts to be paid to the Mexican water authority. As a consequence, first quarter 2012 net income included a $7.2 million after tax benefit ($0.32 per share).
  • Net income for the first quarter 2012 was $28 million compared to $26 million for the prior period. Both the first quarter 2012 (as noted above) and the first quarter 2011 benefited from adjustments to expected water duty charges. Excluding these adjustments, net income was $20 million for the first quarter 2012, compared to $24 million for the prior period with the decline attributable exclusively to lower GTSP & Other profitability.
  • Diluted EPS for the first quarter 2012 was $1.22 compared to $1.15 for the first quarter 2011.  Excluding the water duties items, first quarter 2012 EPS was $0.90 compared to $1.08 for the 2011 first quarter.
  • Randy Gress, CEO of Innophos, commented on the results, "We are pleased with our first quarter results which reflected the strength and flexibility of our business model and continued execution on our strategic initiatives.  The first quarter saw the expected strong recovery in our US/Canada business in comparison to the second half of 2011.  Mexico Specialty Phosphates also continued to perform well with revenues up 12% compared to the 2011 first quarter.  Overall, the profitability of our Specialty Phosphates business has improved from the fourth quarter of 2011 with operating margin up 300 basis points sequentially and both geographic segments at or above their full year 2011 margin levels.

    Mr. Gress concluded, "At the same time, we continued to make good progress on our strategic growth objectives. Our Kelatron business recorded record sales and profitability, with revenue up over 20%, confirming the strong product line and sales channel synergies anticipated for this acquisition. Additionally, in Specialty Phosphates we continued to deliver on our geographic growth objectives in Latin America and Asia while new consumer product launches continued with innovative Innophos Specialty Ingredients including fortified beverages containing VersaCAL® Clear.  Looking ahead to 2012, we are confident that our Specialty Phosphates revenue and profitability will be in line with our long term growth expectations."

    Segment Results first quarter 2012 versus 2011 Specialty PhosphatesSpecialty Phosphates sales revenue was up 10% year over year with prices up 11%. Volume was down 1%, with a 3% benefit from the Kelatron acquisition being offset primarily by lower STPP volumes in Mexico in comparison to a strong first quarter 2011. 

    Operating income at $34 million was $8 million higher sequentially and flat compared to the year ago period.  Operating income margin improved sequentially from 14% to 17%, in line with the 2011 average, but below the advantaged first quarter 2011 margin of 19% that benefited from selling price increases achieved ahead of cost increases.US/CanadaUS/Canada Specialty Phosphates sales increased 9% year over year on higher prices.  Volumes increased 6% sequentially with gains across most markets including the industrial and horticulture applications where demand had weakened at the end of 2011. The encouraging sequential improvement together with the benefit of the Kelatron acquisition delivered overall volumes in line with the strong first quarter last year.Operating income at $27 million was $11 million above fourth quarter 2011 levels, but $3 million below the year ago period.  The favorable comparison sequentially is due to increased volumes, one-off expenses in the 2011 fourth quarter and price increases achieved in the 2012 first quarter ahead of expected cost increases.  Operating income margins at 19% were up 700 basis points sequentially but down 400 basis points on the year ago level.

    MexicoThe Specialty Phosphates business in Mexico achieved 12% higher sales on 18% higher prices, but 6% lower volumes arising from the STPP product line in comparison to a strong first quarter 2011. 

    Operating income at $6 million was up $2 million over year ago levels, but down $3 million sequentially as raw material cost increases caught up with selling price increases achieved in the prior quarter.  Operating income margin was in line with 2011 average margins of 12%, and above the year ago margin of 9%.

    GTSP & OtherGTSP & Other sales (primarily fertilizer co-product) increased 64% on significantly higher volumes, but lower market prices. 

    Operating income was $5 million compared to $7 million in the first quarter 2011.  The 2012 quarter included a $7 million benefit for the Rhodia settlement and the prior year quarter included a benefit of $4 million for updates to the Mexican water duties provision.  Excluding these amounts, an operating loss of $3 million was sustained for the 2012 quarter compared to a profit of $3 million for the first quarter 2011. 

    Recent Trends and OutlookUnderlying demand conditions continued to be favorable for Specialty Phosphates with market demand in most sectors seen as stable to moderately improving. Management continues to expect above market volume growth of 4-6% for 2012 driven by product innovation and geographic growth.

    The Specialty Phosphates business continued to achieve price increases into the first quarter and we will continue to maintain a close watch on fertilizer market trends and their potential impact on our raw material costs. Currently, we do not expect significant sequential price increases in the second quarter, and our primary focus is now on continuing to deliver against our growth goals, both geographically and through product innovation. However, if the very recent signs of improving fertilizer conditions gain momentum and look likely to create further upward pressure on raw material costs for the second half of 2012, then we will be ready to respond as necessary.

    The time lag between changes in market raw material prices and their effect on Innophos' contract raw material prices will result in a sequential increase of approximately $4-6 million in Innophos' cost of goods sold in the second quarter, primarily affecting the US/Canada business.  This will affect second quarter margins unfavorably compared to the first quarter. Overall for the year, however, management continues to expect 2012 operating income growth for Specialty Phosphates in line with 7-10% long term expectations. 

    Recent industry publications have reported improved fertilizer demand and pricing for the second quarter as the industry enters the seasonally stronger demand months, although prices remain significantly below year ago levels. These market trends are expected to contribute to a sequential improvement in GTSP & Other margins resulting in expected operating income around break-even for this segment on sales of $20-25 million for the second quarter.

    Net debt decreased $21 million in the first quarter 2012 on strong earnings and a moderate seasonal increase in working capital. Management expects strong operating cash flow generation in 2012 with a moderate reduction in working capital levels and capital expenditures expected to be below depreciation levels. 

    Capital Expenditures Capital expenditures were $5 million in the 2012 first quarter and management now expects to spend approximately $40 million for all of 2012.  Investment continues to be focused on debottlenecking US / Canada and Mexico Specialty Ingredients facilities, expanding geographically including the investment in China, and enhancing Mexico's capability to process multiple grades of rock, consistent with the Company's supply chain diversification strategy.

    Rhodia Settlement over Mexican Water FeesDuring the first quarter 2012 Innophos settled with Rhodia, Inc. and its parent company, Rhodia, S.A., all issues concerning indemnity claims for water fees by the Mexican national water commission (CNA), certain port concession fees, and all other matters in related litigation filed by Innophos and pending between the companies in the New York courts since 2005.

    Separately, Innophos reached agreement with the CNA and began paying agreed sums disposing of the CNA claims for 2009 through 2011 for lesser amounts than previously accrued for those years.  CNA also issued resolutions seeking fees, interest and penalties for the periods 2005-2008 in amounts similar to those previously accrued by Innophos. In April, our affiliate, Innophos Fosfatados, filed claims in Mexican courts seeking to nullify the 2005-2008 claims due to flaws in the substance, process and timing of the CNA resolutions.

    After reducing the company's estimate for the amounts expected to be claimed by the CNA and after including the benefits of the 2012 Rhodia settlement, the Company recorded a $7.2 million benefit in the first quarter 2012.

    About Innophos Holdings, Inc.Innophos is a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, pharmaceutical, oral care and industrial end markets. Innophos combines more than a century of experience in specialty phosphate manufacturing with a growing capability in a broad range of other mineral ingredients to supply a product range produced to stringent regulatory manufacturing standards and the quality demanded by customers worldwide. Innophos is continually developing new and innovative specialty ingredients addressing specific customer applications and supports these high-value products with industry-leading technical service.  Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations in Nashville, TN; Chicago Heights, IL; Chicago (Waterway), IL; Geismar, LA; Ogden, UT; Port Maitland, ON (Canada); Coatzacoalcos, Veracruz and San Jose de Iturbide (Mission Hills), Guanajuato (Mexico). For more information please visit 'IPHS-G'

    Financial Tables FollowInnophos Holdings, Inc.FTI Consulting, Inc.Investor Relations: (609) 366-1299Alexandra Tramont/Matt Steinberginvestor.relations@innophos.com212-850-5600 Conference Call DetailsThe conference call is scheduled for Wednesday, May 2, 2012 at 10:00 am ET and can be accessed by dialing 888-713-4211 (U.S.) or 617-213-4864 (international) and entering passcode 43186989.  Please dial in approximately 15 minutes ahead of the start time to ensure timely entry to the call.  A replay will be available between 1:00 pm ET on May 2 and 1:00 pm ET on May 16, 2012.  The replay is accessible by dialing 888-286-8010 (U.S.) or 617-801-6888 (international) and entering passcode 18705591.

    Safe Harbor for Forward-Looking and Cautionary Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.  As such, final results could differ from estimates or expectations due to risks and uncertainties, including but not limited to: incomplete or preliminary information; changes in government regulations and policies; continued acceptance of Innophos' products and services in the marketplace; competitive factors; technological changes; Innophos' dependence upon first-party suppliers; and other risks.  For any of these factors, Innophos claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, as amended.

    Summary Profit & Loss Statement – First Quarter INNOPHOS HOLDINGS, INC. AND SUBSIDIARIESCondensed Consolidated Statement of Operations (Unaudited)(Dollars In thousands, except per share amounts or share amounts)Three months endedThree months endedMarch 31, March 31, 20122011Net sales

    $228,252$197,598Cost of goods sold

    172,384140,269Gross profit

    55,86857,329Operating expenses:
    Selling, general and administrative

    Research & development expenses

    Total operating expenses

    17,72916,507Operating income

    38,13940,822Interest expense, net

    1,6271,303Foreign exchange (gain) loss

    (291)710Income before income taxes

    36,80338,809Provision for income taxes

    9,21512,840Net income

    $27,588$25,969Diluted Earnings Per Share

    $1.22$1.15Diluted weighted average common shares outstanding:

    22,699,74522,612,342Dividends paid per share of common stock

    $0.25$0.17Dividends declared per share of common stock

    $0.27$0.25Segment Reporting – First Quarter The Company reports its operations in three segments: Specialty Phosphates - US/Canada, Specialty Phosphates - Mexico and GTSP & Other.  The primary performance indicators for the chief operating decision maker are sales and operating income, with sales on a ship-from basis.  The following table sets forth the historical results of these indicators by segment:Three months endedThree months endedMarch 31, March 31, Net Sales20122011% ChangeSegment Net SalesSpecialty Phosphates US & Canada

    $141,594$130,3448.6%Specialty Phosphates Mexico

    50,92845,50211.9%Total Specialty Phosphates

    192,522175,8469.5%GTSP & Other


    $228,252$197,59815.5%Segment Operating IncomeSpecialty Phosphates US & Canada

    $27,236$29,822Specialty Phosphates Mexico

    6,2623,970Total Specialty Phosphates

    33,49833,792GTSP & Other (a)


    $38,139$40,822Segment Operating Income %  of net salesSpecialty Phosphates US & Canada

    19.2%22.9%Specialty Phosphates Mexico

    12.3%8.7%Total Specialty Phosphates

    17.4%19.2%GTSP & Other (a)


    16.7%20.7%Depreciation and amortization expenseSpecialty Phosphates US & Canada

    $5,371$4,834Specialty Phosphates Mexico

    3,7723,924Total Specialty Phosphates

    9,1438,758GTSP & Other


    $10,239$10,194(a) The three months ended March 31, 2012 includes a $7.1 million benefit to earnings primarily
    for the settlement with Rhodia on their liability for the charges to be paid to the CNA.

    The three months ended March 31, 2011 includes a $3.8 million benefit to earnings related to

    updates to the provision for the CNA Fresh Water Claims.
    Price / Volume – First Quarter The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume.  The current quarter selling price dollar variance is derived from the current quarter year to date selling price dollar variance less the previous quarter year to date selling price dollar variance.  The selling price dollar variance is then divided by the prior period sales dollars to calculate the percentage change.  Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix.

    The following tables illustrate for the three months ended March 31, 2012 the percentage changes in net sales by reportable segments and by Specialty Phosphates product lines compared with the same period of the prior year, including the effect of selling price and volume/mix changes upon revenue:Reportable Segments  Price
    Volume/Mix  Total
    Specialty Phosphates US & Canada

    8.4%0.2%8.6%Specialty Phosphates Mexico

    18.0%-6.1%11.9%Total Specialty Phosphates

    10.9%-1.4%9.5%GTSP & Other


    8.7%6.8%15.5%Note: 2012 includes Kelatron in Specialty Phosphates US & Canada Volume/MixSpecialty Phosphates Product Lines  Price
    Volume/Mix  Total
    Specialty Ingredients

    8.7%-0.2%8.5%Food & Technical Grade PPA

    15.0%2.4%17.4%STPP & Detergent Grade PPA

    15.9%-12.6%3.3%Note: 2012 includes Kelatron in Specialty Ingredients Volume/MixSummary Cash Flow StatementINNOPHOS HOLDINGS, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Cash Flows (Unaudited)(Dollars in thousands)Three months endedThree months endedMarch 31, March 31, 20122011Cash flows from operating activities
    Net income

    Adjustments to reconcile net income to net cash provided from operating activities:

    Depreciation and amortization

    Amortization of deferred financing charges

    Deferred income tax provision

    Deferred profit sharing

    Share-based compensation

    1,2212,273Changes in assets and liabilities:
    Increase in accounts receivable

    Decrease in inventories

    Decrease in other current assets

    Decrease in accounts payable

    Decrease in other current liabilities

    (20,780)(6,131)Changes in other long-term assets and liabilities

    (3,488)(2,473)Net cash provided from operating activities

    29,86031,321Cash flows from investing activities:
    Capital expenditures

    (5,200)(7,307)Net cash used for investing activities

    Cash flows from financing activities:

    Proceeds from exercise of stock options

    Long-term debt borrowings

    Long-term debt repayments

    Excess tax benefits from exercise of stock options

    Common stock repurchases

    Dividends paid

    (5,405)(3,649)Net cash provided from (used) for financing activities

    634(7,091)Net change in cash

    25,29416,923Cash and cash equivalents at beginning of period

    35,24263,706Cash and cash equivalents at end of period

    $60,536$80,629Summary Balance SheetsINNOPHOS HOLDINGS, INC. AND SUBSIDIARIESCondensed Consolidated Balance Sheets (Unaudited)(Dollars In thousands)March 31,
    2012December 31,
    2011ASSETSCurrent assets:
    Cash and cash equivalents

    Accounts receivable - trade


    Other current assets

    Total current assets

    391,996384,707Property, plant and equipment, net


    61,55461,587Intangibles and other assets, net

    Total assets

    $690,808$687,015LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:
    Current portion of long-term debt

    Accounts payable, trade and other

    Other current liabilities

    Total current liabilities

    85,213108,249Long-term debt

    152,000148,000Other long-term liabilities

    Total liabilities

    Total stockholders' equity

    Total liabilities and stockholders' equity

    $690,808$687,015Additional InformationNet debt is a supplemental financial measure that is not required by, or presented in accordance with, USGAAP.  The Company believes net debt is helpful in analyzing leverage and as a performance measure for purposes of presentation in this release. The Company defines net debt as total long-term debt (including any current portion) less cash and cash equivalents.


    SOURCE Innophos Holdings, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Innophos to Present at 2010 Oppenheimer Industrials Conference
    2. China Pharma Holdings, Inc. Will Attend the Susquehanna Financial Group, LLP (SIG) Beijing Management Summit
    3. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
    4. China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%
    5. China Pharma Holdings, Inc. Appoints The Ruth Group
    6. BioAuthorize Holdings, Inc. Names New Directors and Executive and Unveils Modification to Its Voice Biometric Authentication Service
    7. China Pharma Holdings, Inc. to Present at Two Upcoming U.S. Investor Conferences
    8. China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin Enteric-Coated Capsules
    9. China Pharma Holdings, Inc. Announces Clinical Trials Already Underway for Candesartan
    10. JAG Media Holdings, Inc. Announces Letter of Intent for the Acquisition of CardioGenics Inc. by a Wholly-Owned Subsidiary of JAG Media
    11. EFT BioTech Holdings, Inc.s Subsidiary Receives First Permit to Cross Taiwan Strait
    Post Your Comments:
    (Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
    (Date:10/10/2017)... ... October 10, 2017 , ... For the second time in ... STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, ... , US2020’s mission is to change the trajectory of STEM education in America ...
    (Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
    (Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
    Breaking Biology Technology:
    (Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
    (Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
    (Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
    Breaking Biology News(10 mins):